E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 25.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10055577 |
E.1.2 | Term | Obstructive sleep apnea syndrome |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
50% reduction in apnea/hypopnea index (AHI) after 1 month of treatment compared to baseline. |
|
E.2.2 | Secondary objectives of the trial |
Significant improvements on different psychometric measurements (PSQI, ESS, FSS, FOSQ) as well as on other polysomnographic respiratory parameters (snoring, oxygen desaturation index – ODI, time spent below 90% oxygen saturation). Furthermore, we expect a good tolerance profile with a low number of drop-outs due to side effects. Finally, polysomnographic parameters related to sleep structure and quality (total sleep time – TST, sleep onset latency – SOL, wake time after sleep onset – WASO, sleep efficiency – SE, proportions of light sleep – N1/N2, deep sleep – N3, REM sleep, micro arousal index – MAI, intrusions of alpha waves in delta sleep) will be monitored. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients between 18 and 70 years suffering from moderate OSA (AHI 15 – 30/hour) diagnosed by a full in-hospital polysomnography (PSG).
- Inclusion of patients should occur after a negative highly sensitive pregnancy test. Women of child bearing age (WOCBP) should use a highly effective method of contraception preferably with low user dependency*. Contraception should be maintained during treatment and until the end of relevant systemic exposure (day 30). Male healthy volunteers with a WOCBP partner should use a condom during treatment and until the end of relevant systemic exposure in WOCBP.
*Birth control methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include: - combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation 1: o oral o intravaginal o transdermal - progestogen-only hormonal contraception associated with inhibition of ovulation: o oral o injectable o implantable - intrauterine device (IUD) - intrauterine hormone-releasing system ( IUS) - bilateral tubal occlusion - vasectomised partner (provided that partner is the sole sexual partner of the WOCBP trial participant and that the vasectomised partner has received medical assessment of the surgical success). - sexual abstinence (only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments: 30 days. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject).
|
|
E.4 | Principal exclusion criteria |
- Non-stabilized cardiovascular disorders - Medical history of urinary retention, intestinal occlusion, glaucoma, epilepsy, neurodegenerative disorders, unipolar and bipolar mood disorders. - Ongoing pharmacological treatments: antidepressants, antiepileptic drugs, antiparkinsonian drugs. - Ongoing treatment for Obstructive sleep apnea - Diagnosis of central sleep apnea (CSA) at baseline polysomnography - Pregnancy - Professional drivers |
|
E.5 End points |
E.5.1 | Primary end point(s) |
50% reduction in apnea/hypopnea index (AHI) after 1 month of treatment compared to baseline. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
after 1 month of treatment |
|
E.5.2 | Secondary end point(s) |
Significant improvements on different psychometric measurements (PSQI, ESS, FSS, FOSQ) as well as on other polysomnographic respiratory parameters (snoring, oxygen desaturation index – ODI, time spent below 90% oxygen saturation). Furthermore, we expect a good tolerance profile with a low number of drop-outs due to side effects. Finally, polysomnographic parameters related to sleep structure and quality (total sleep time – TST, sleep onset latency – SOL, wake time after sleep onset – WASO, sleep efficiency – SE, proportions of light sleep – N1/N2, deep sleep – N3, REM sleep, micro arousal index – MAI, intrusions of alpha waves in delta sleep) will be monitored. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
after 1 month of treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |